Overview
Click Here to View the Program
Member fees will be applied to members of Forum for Innovative Regenerative Medicine (FIRM) as well as to DIA members. Please send the application form to DIA Japan office by fax or e-mail.
1st DIA Cell Therapy Products Symposium in Japan: Industry, Academia, and Government Challenges in Practical Use
In Japan, development of regenerative medicine has gained much attention since Professor Shinya Yamanaka won the Nobel Prize for his research in induced pluripotent stem (iPS) cells in 2012. In 2013, relevant regulatory and legal systems corresponding to early practical use of regenerative medicine were established.
After implementation of the Pharmaceutical and Medical Device Act in 2014, pharmaceutical companies, including venture companies based in academia, have actively undertaken regenerative medical product development. At the same time, issues concerning development and/or distribution of such products have been recognized from the international and strategic points of view.
The 1st DIA Cell Therapy Products Symposium in Japan will bring together all stakeholders working in developing regenerative medical products, in particular those from industry and academia, to share clues and exchange ideas with relevant government authorities to deepen their mutual understanding and solve these issues of concern. By examining previous frameworks and experiences in Japan and elsewhere, panelists will guide participants through active discussions of appropriate business and development strategies that will result in well-balanced, international regenerative medical product development and business.
As practical use of regenerative medical products has just begun, continued discussion with relevant government authorities on quality control, development, marketing, and other strategic issues will lead to better clues that solve these problems. Your active participation is highly appreciated.
Featured
Want to learn more about 1st DIA Cell Therapy Products Symposium in Japan? You've come to the right site!
Program Committee
-
Yoji Sato, PhD Head, Division of Drugs
National Institute of Health Sciences, Japan -
Akiko Ikeda, RPh Associate Director, Regulatory Development Dept.
Janssen Pharmaceutical K.K., Japan -
Teruyo Arato, PhD Professor, Clinical Research and Medical Innovation Center
Hokkaido University Hospital, Japan -
Keiji Miyamoto Principal Post-Marketing Regulatory Affairs Dep.
Daiichi Sankyo Co.,Ltd., Japan -
Tadashi Sameshima Executive Officer/GM HeartSheetBusiness Dept, Project Leader, R&D
Terumo Corporation, Japan -
Masayuki Shibasaki, PhD Special Advisor
Life Science Innovation Network Japan, Inc., Japan -
Kazuhiro Takekita Instructor, Department of Cardiovascular Surgery, Graduate School of Medicine,
Osaka University, Japan -
Yasuko Terao, PhD Head, External Scientific Engagement, R&D Japan Region,
Takeda Pharmaceutical Co., Ltd., Japan -
Yoshie Tsurumaki Group Manager, Cell & Gene Franchise
Novartis Pharma K.K., Japan
Have an account?